FDA’s Compassionate Use Policy: Is Tysabri A Precedent Or A Special Case?

When FDA stepped in and helped prominent trial lawyer and Democratic fundraiser Fred Baron get access to Tysabri for off-label treatment of his multiple myeloma, it raised questions about whether the agency had adopted a new policy